Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Catalyst Pharmaceutical (CPRX) closed the last trading session at $24.96, gaining 0.5% over the past four weeks, but there ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

FIRDAPSE boosts Catalyst's strong Q1 2025 results, beating forecasts. With 15–20% growth projected, see why analysts rate ...

This was the stock's second consecutive day of gains.

In 2025, the catalyst bins market is estimated to be valued at approximately USD 39,086.58 million. Looking ahead to ...

This was the stock's second consecutive day of gains.

Catalyst Pharmaceuticals Inc. stock grades by Barron's. View CPRX fundamental and sentiment analysis powered by MarketGrader.

Catalyst Pharmaceuticals reported a robust start to 2025 with earnings per share (EPS) of $0.68, doubling the forecast of $0.34. Revenue reached $141.4 million, surpassing expectations of $131.54 ...

CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2025 and ...

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

Commonwealth Equity Services LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 133.1% in the fourth quarter, according to the company in its most recent ...